Trehalose-based Siamese twin amphiphiles with tunable self-assembling, DNA nanocomplexing and gene delivery properties by Carbajo-Gordillo, Ana I. et al.
Registered charity number: 207890
rsc.li/chemcomm
 Showcasing research from the groups of Profs. C. Ortiz Mellet, 
C. Tros de Ilarduya, and J. M. García Fernández, 
Universities of Sevilla, Navarra, and the CSIC 
(Institute of Chemical Research), Spain. 
 Trehalose-based Siamese twin amphiphiles with tunable 
self-assembling, DNA nanocomplexing and gene delivery 
properties 
 The disaccharide trehalose is a geminated scaffold suitable 
for the synthesis of molecularly defined conjoined (“Siamese”) 
twin amphiphiles capable of condensing DNA into transfectious 
nanocomplexes; depending on the architectural properties, 
diverse topologies can be programmed resulting in selective 
 in vivo tropisms. 
As featured in:
ISSN 1359-7345
 COMMUNICATION 
 You-Xuan Zheng  et al . 
 Chiral iridium(III) complexes with four-membered Ir–S–P–S 
chelating rings for high-performance circularly polarized 
OLEDs 
ChemComm
Chemical Communications
rsc.li/chemcomm
Volume 55 Number 57 21 July 2019 Pages 8193–8338
See Concepción Tros de Ilarduya, 
Carmen Ortiz Mellet, 
José M. García Fernández  et al ., 
 Chem .  Commun ., 2019,  55 , 8227.
This journal is©The Royal Society of Chemistry 2019 Chem. Commun., 2019, 55, 8227--8230 | 8227
Cite this:Chem. Commun., 2019,
55, 8227
Trehalose-based Siamese twin amphiphiles with
tunable self-assembling, DNA nanocomplexing
and gene delivery properties†
Ana I. Carbajo-Gordillo, ‡a Julio Rodrı´guez-Lavado, ‡b
Jose´ Luis Jime´nez Blanco, b Juan M. Benito, a Christophe Di Giorgio, c
Itziar Ve´laz, d Concepcio´n Tros de Ilarduya, *e Carmen Ortiz Mellet *b and
Jose´ M. Garcı´a Ferna´ndez *a
An original family of multivalent vectors encompassing gemini and
facial amphiphilicity, namely cationic Siamese twin surfactants, has
been prepared from the disaccharide trehalose; molecular engineering
lets us modulate the self-assembling properties and the topology of
the nanocomplexes with plasmid DNA for eﬃcient gene delivery
in vitro and in vivo.
The approval of several gene therapy treatments by regulatory
agencies and the promising results obtained in recent clinical
trials in areas like cancer, epilepsies, hemophilia, retinal
degeneration, Parkinson’s disease or metabolic disorders have
strongly nurtured expectations of a new age for personalized
medicine.1 The main hurdle for these channels is the lack of
delivery vectors capable of eﬃciently and safely transporting
the therapeutic gene material to enforce the desired genetic
change in the target cells. Despite great progress, viral systems
still raise concerns about immunogenicity, random integration
in the host genome, limited DNA packaging capacity and the
cost of clinical grade production of large batches.2 Non-viral
carriers have the potential to address most of these limitations3
and some are currently being applied in a number of clinical
trials.4 However, most of them are intrinsically polydisperse in
nature (e.g., cationic polymers), lack conformational definition
(e.g., cationic dendrimers) and/or require multicomponent
formulation (e.g., cationic lipids), which hampers precise struc-
ture–efficiency relationship and optimization studies. Cationic
multivalent surfactants with well-defined molecular structures,5
amongwhich cyclodextrin (CD) derivatives are archetypal examples,6
epitomize remarkable exceptions. Their giant amphiphilic sur-
face exposes facially segregated cationic and lipophilic domains
that concertedly drive co-assembly with nucleic acids (Fig. 1A);
however, keeping diastereomeric purity can be significantly
demanding.7 This problem is largely mitigated for the cationic
lipid dimers generically termed gemini surfactants,8 the smallest
representatives of multivalent amphiphiles (Fig. 1B). Gemini
surfactants have proven to be superior to their monomeric
counterparts as gene vectors, but unlike their rigid higher-
valent facial amphiphilic homologues they generally require a
helper lipid to accomplish the task.9 Most importantly, the
topological properties and stability of multivalent and gemini-
based supramolecular aggregates exhibit a strong dependence
on vector structure and local pH, enabling control over cell
uptake and cargo release.7–9 Here we report that the disaccharide
a,a0-trehalose, a C2-symmetrical glucose dimer, can be engineered
through modular ‘‘click’’ strategies to access ‘‘Siamese twin’’
surfactants amalgamating the advantages of gemini and facial
amphiphilicity for efficient DNA nanocomplexation and delivery
in vitro and in vivo (Fig. 1C).
The structure/activity relationship data collected during the
last decade for cyclooligosaccharide-based gene delivery sys-
tems indicate that facially diﬀerentiated constructs consisting
Fig. 1 Schematic representations of CD-based multivalent facial amphi-
philes (A), gemini surfactants (B) and the novel a,a0-trehalose Siamese twin
amphiphiles (C).
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of monosaccharide units bearing hexanoyl chains at secondary
positions and a bifurcated presentation of amino groups at the
primary position are particularly favorable.10 This combination
of functional elements provides an appropriate hydrophilic/
hydrophobic balance and an optimal density of cationizable
centers for eﬃcient interaction with the polyphosphate back-
bone in the nucleic acid partner.11 We capitalized on this back-
ground to develop a set of new trehalose-based Siamese twin
prototypes 6–10 (Scheme 1). The rationale is that specific arrange-
ments of flexible spacers (cysteaminyl, ethylene segments), pH
buffering groups (triazole heterocycles, tertiary amines), hydro-
gen bonding modules (thiourea motifs) and peripheral primary
amines can translate into distinct self-assembling properties,
plasmid DNA (pDNA) complexing abilities and vector/pDNA
nanocomplex topologies, thereby impacting transfection cap-
abilities and providing information on the molecular determi-
nants of efficient gene delivery.5
The target gemini facial surfactants 6–10 were synthesized
from the 6,60-diazido-, 6,60-di-(2-aminoethylthio)- or 6,60-di-(2-
azidoethylthio)-a,a0-trehalose derivatives 1–3 and the alkyne- or
isothiocyanate-armed partners 4 and 5 through copper(I)-catalyzed
azide–alkyne coupling (CuAAC) and thiourea-forming ‘‘click’’
reactions, respectively (Scheme 1 and ESI†). Their capacity to
complex and protect pDNA was initially investigated by electro-
phoresis mobility shift assay (EMSA) in polyacrylamide gel, using
the intercalating agent GelReds for visualization. Trehalose
vector/pDNA formulations were prepared at protonatable nitro-
gen/anionic phosphate (N/P) ratios of 5, 10 and 20. In all cases,
full pDNA complexation, compaction, and protection was achieved,
as inferred from the capacity of the compounds to arrest migration
of pDNA in the gel, the inability of the fluorescent intercalating
agent GelReds to access the pDNA cargo in the complexes and the
recovery of the essentially unaltered pDNA after DNase I/sodium
dodecylsulfate (SDS) treatment (Fig. 2B). However, compounds 6
at N/P 5 and 10 and 9 at N/P 5 did not provide stable colloidal
suspensions under the conditions used for nanocomplex formula-
tion (Tables S1–S3, ESI†). To ensure a uniform regime, N/P 20
formulations were employed for comparative studies of molecular
structure/self-assembly/pDNA nanocomplex topology/gene delivery
efficiency relationships.
Compound 6, featuring a rigid triazole moiety connecting the
disaccharide core and the cationic arms, aﬀorded stable homo-
geneous nanospheres of 15 nm diameter (TEM) in aqueousmedia,
a typical behavior of ‘‘conical’’ surfactants.12 In the presence of
pDNA, morula-like nanoplexes of 120–140 nm diameter were
formed, suggesting that interaction of the intact vector nano-
spheres with the polyphosphate chain drives compaction of the
plasmid (Fig. 3A and B; left panel). Under identical conditions,
the homologous derivative 7 afforded 50 nm vesicles that, upon
co-formulation with pDNA, reorganized into spherical nano-
particles (80–100 nm in diameter) exhibiting an alternating
arrangement of glycolipid bilayers and plasmid chains (Fig. 3A
and B; middle panel). The insertion of a flexible cysteaminyl
spacer between the trehalose scaffold and the cationic antennae
in compounds 8–10 drastically reduced the predisposition to
form defined self-assembled aggregates. In the presence of pDNA,
8 and 9 afforded spherical nanocomplexes similar in size and
ultrathin structure to those obtained from 7. Compound 10
exhibited a singular behavior: neat samples showed the presence
of bilayer structures characteristic of tubular shaped amphiphiles,
whereas in co-formulation with pDNA spherical core–shell nano-
particles (70–80 nm diameter) with a variable level of internal
order were formed (Fig. 3A and B; right panel). This scenario
strongly suggests a biomimetic two-step mechanism analogous to
that characterizing the co-assembly of enveloped viruses:13 first,
the ‘‘en masse’’ interaction of individual molecules of 10 with the
nucleic acid takes place and then the external unilamellar shell of
the amphiphile forms. Nanostructures of such a type have been
previously assembled by sophisticated multiformulation strate-
gies and found to be particularly efficient for nucleic acid cargo
delivery to target cells.14
Dynamic light scattering (DLS) and mixed mode measurement
phase analysis light scattering (M3-PALS) provided hydrodynamic
Scheme 1 Synthesis of the Siamese twin cationic glycolipids 6–10 from
precursors 1–5.
Fig. 2 EMSA gels for formulations with 6–10 and pDNA at N/P 20 before
(A) and after DNAase I/SDS treatment (B). Virtually identical patterns were
obtained at N/P 5 and 10.
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diameters slightly higher than those measured by TEM for the
above N/P 20 formulations, with polydispersity index values ofo0.3
(Table S3, ESI†) and positive z-potential values (+21 to +37 mV).
The transfection eﬃciency of a gene vector depends not only
on the stability of the corresponding complexes with nucleic acids
in the extracellular milieu (pH E 7) but also on its capability to
promote endosomal escape and timely cargo release after cell
uptake (pH E 5). Multivalent facial amphiphiles, including
gemini surfactants, experience increasing electrostatic repul-
sions upon acidification, resulting in destabilization of the pDNA
co-assemblies.7,8 Individual components can then interact with
the endosome membrane, provoking disruption and DNA leak-
age into the cytoplasm. The new hybrid vectors 6–10 were
anticipated to benefit from this mechanism. Indeed, the TEM
micrographs recorded at pH 5 (Fig. 3C) revealed aggregates with
much less defined internal arrangements. DLS measurements
further showed a significant increase in polydispersity and the
appearance of higher size nanoparticle populations, altogether
supporting decreased stability (Fig. S13, ESI†).
pH-Responsiveness was further checked by titration experi-
ments (Fig. S14, ESI†). Compounds 7 and 10, displaying
aminoethylthiourea peripheral branches, exhibitedmuch stronger
buﬀering capabilities, determined as the meq. of NaOH required
to switch a 50 mM solution (referring to the total number of
protonatable amino groups in the vector) from pH 5 to pH 7, as
compared with their homologues 6 and 9 (181.6 and 195.0 versus
61.2 and 85.6 meq., respectively). The buﬀering potentials of 7
and 10 are even higher than that of branched polyethyleneimine
(bPEI 25 kDa; 134.4 meq.),11,15 a cationic polymer used as gold
standard for nonviral gene delivery across multiple studies.16 A
proton sponge mechanism, resulting in swelling and disruption
on progressing from the early to the late endosome state, has
been postulated for PEI polyplexes and likely also facilitates
endosomal escape in the present case.17
The transfection eﬃciency of the Siamese twin vectors 6–10
was initially assessed in COS-7 primate epithelial kidney cells and
HepG2 human hepatocarcinoma cells. PEI and the CD-based
vector ADM70 (Fig. S15, ESI†), one of the most efficient multi-
valent molecular vectors reported to date,18 as well as naked pDNA
(luciferase encoding), were used as positive and negative controls,
respectively (Fig. 4A). Formulations prepared from 7 or 10 at N/P
20 were clearly superior to those elaborated from 6 or 9, having
identical numbers of cationic centers, in both cell lineages, spot-
lighting the aminoethylthioureido motif as a preferred functional
element in multivalent gene delivery system prototypes. The
10/pDNA nanocomplexes were the most efficient in these
experimental settings, promoting 10- and 1.2-fold higher levels
of luciferase expression as compared to bPEI in COS-7 and HepG2
cells, respectively. They also rivalled the transfection proficiency of
ADM70/pDNA complexes. Compound 10 further compared favor-
ably with PEI and Lipofectamine 3000s (a commercial cationic
lipid formulation) in murine embryonic hepatocyte BNL-CL2 and
macrophage RAW 264.7 cells, which are notably more resistant to
transfection. Only ADM70 in BNL-CL2 cells was superior. Impor-
tantly, irrespective of the trehalose-based vector structure, all the
pDNA formulations showed low cytotoxicities (Alamar blues and
MTT cell viabilities 480% and 470%, respectively, except for 6;
Fig. S16A and B, ESI†). The best performing vector 10 was next
assessed for its ability to complex the plasmid pCMVIL12, which
encodes the potent antitumoral cytokine interleukin-12 (IL-12),19
and deliver it into HepG2 cells. The corresponding nanocom-
plexes (N/P 20) performed about 30% better than bPEI in this
assay (Fig. 4B).
The possibility of molding the topological properties at the
nanoscale level by acting on the molecular structure of the vector
oﬀers unique opportunities to aﬀect the tropism of the nano-
particles in vivo. To explore this issue, nanocomplexes formulated
with 8 (spherical multilayered) or 10 (spherical core–shell) at N/P
20 were next injected systemically into mice, and their activity was
compared with PBS and the naked DNA as negative controls. The
results, based on the luciferase reporter gene expression, indi-
cated that 24 h after the intravenous administration, transfection
occurred mainly in the liver in the case of 8, which is consistent
with previous data for CD-based vectors affording nanocomplexes
with similar topology.8 In sharp contrast, compound 10 promoted
transfection in the lung (Fig. 4B), an important target in gene
therapy,20 with negligible luminescence detected in other organs,
Fig. 3 3D molecular models of the gemini facial amphiphiles 6, 7 and 10
and representative TEM micrographs of the corresponding self-assembled
(A) and pDNA co-assembled aggregates at pH 7 (B) and pH 5 (C). Schematic
representations of the initial interactions with the plasmid and of the final
nanoassemblies (pH 7) are provided in the arrows and the inserts, respec-
tively. Control TEM experiments and larger micrographs of the vector/pDNA
nanocomplexes are collected in Fig. S12, ESI.†
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highlighting the potential of nanocomplex topology control through
molecular vector tailoring for tissue-specific gene delivery.
Polyplexes obtained with bPEI exhibited 100% mortality in
this assay, whereas all mice survived treatment with formula-
tions containing the trehalose-based Siamese twin amphiphiles.
Taken together, the results provide a testable prototype to guide
future molecular vector design.
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